Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1

By /

Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.

Scroll to Top